Norris Medicines Closes Trading Window Ahead of Q1 Results

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, and key managerial personnel, effective July 1, 2026. This closure is in accordance with the company's code of conduct for prohibiting insider trading, aligned with SEBI regulations. The trading window will reopen 48 hours after the public declaration of the un-audited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately. During the closure, all designated individuals are prohibited from trading in the company's securities.